Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa

J Infect Dis. 2013 Jan 1;207(1):9-17. doi: 10.1093/infdis/jis631. Epub 2012 Nov 19.

Abstract

Background: Extensively drug-resistant tuberculosis (XDR-tuberculosis) is a global public health threat, but few data exist elucidating factors driving this epidemic. The initial XDR-tuberculosis report from South Africa suggested transmission is an important factor, but detailed epidemiologic and molecular analyses were not available for further characterization.

Methods: We performed a retrospective, observational study among XDR-tuberculosis patients to identify hospital-associated epidemiologic links. We used spoligotyping, IS6110-based restriction fragment-length polymorphism analysis, and sequencing of resistance-determining regions to identify clusters. Social network analysis was used to construct transmission networks among genotypically clustered patients.

Results: Among 148 XDR-tuberculosis patients, 98% were infected with human immunodeficiency virus (HIV), and 59% had smear-positive tuberculosis. Nearly all (93%) were hospitalized while infectious with XDR-tuberculosis (median duration, 15 days; interquartile range: 10-25 days). Genotyping identified a predominant cluster comprising 96% of isolates. Epidemiologic links were identified for 82% of patients; social network analysis demonstrated multiple generations of transmission across a highly interconnected network.

Conclusions: The XDR-tuberculosis epidemic in Tugela Ferry, South Africa, has been highly clonal. However, the epidemic is not the result of a point-source outbreak; rather, a high degree of interconnectedness allowed multiple generations of nosocomial transmission. Similar to the outbreaks of multidrug-resistant tuberculosis in the 1990s, poor infection control, delayed diagnosis, and a high HIV prevalence facilitated transmission. Important lessons from those outbreaks must be applied to stem further expansion of this epidemic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Cluster Analysis
  • Cross Infection / complications
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Cross Infection / transmission*
  • Drug Therapy, Combination
  • Ethambutol / therapeutic use
  • Extensively Drug-Resistant Tuberculosis / complications
  • Extensively Drug-Resistant Tuberculosis / epidemiology
  • Extensively Drug-Resistant Tuberculosis / microbiology
  • Extensively Drug-Resistant Tuberculosis / transmission*
  • Female
  • Genotype
  • HIV Infections / complications*
  • HIV Infections / virology
  • Hospitals, Rural
  • Humans
  • Isoniazid / therapeutic use
  • Male
  • Mutation
  • Mycobacterium tuberculosis / classification*
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / isolation & purification
  • Polymorphism, Restriction Fragment Length
  • Prevalence
  • Pyrazinamide / therapeutic use
  • Retrospective Studies
  • Rifampin / therapeutic use
  • Sequence Analysis, DNA
  • South Africa / epidemiology

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin